TLC to Present at Upcoming Conferences
Solebury Trout Class of 2018 Biotech IPOs Investor Day
Location: Davis Polk Offices [
Dates: Thursday - Sunday,
Location: Sheraton Centre Toronto [123 Queen St W,
Title: Single Intraarticular Injection of TLC599 Provided Sustained Pain Relief through 24 Weeks in Participants with Symptomatic Knee Osteoarthritis
Location: Grand Ballroom West
Title: Cartilage Damage and Synovial Toxicokinetic Study of a Sustained Release Liposomal Formulation of Dexamethasone Sodium Phosphate (TLC599) following Intraarticular Injection in Healthy Dogs and Rabbits
Location: Sheraton Hall / Osgoode & Foyers
Jefferies-Fubon Corporate Access Day
Location: Conrad Hong Kong [88 Queensway, Admiralty,
A copy of the TLC presentation and the poster and oral presentations from OARSI can be accessed by under “News and Events” in the Investors section of TLC’s website at www.tlcbio.com.
TLC (Nasdaq: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™). TLC believes that its deep experience with liposome science allows TLC to combine onset speed and benefit duration, and improve active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX™ active drug loading technology is designed to alter the systemic exposure of the drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.
+886 2 2655 7377 ext. 136
+1 646 378 2975